ACTRN12614001265662
Terminated
未知
The efficacy of palliative radiotherapy on symptomatic response as measured by PET scan and self-assessed pain response for patients with malignant pleural mesothelioma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Sir Charles Gairdner Hospital
- Enrollment
- 40
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histologically or cytologically confirmed malignant pleural mesothelioma (MPM
- •Patients with focal clinical symptoms likely to be caused by MPM as confirmed by prior imaging imaging (including non\-pleural metastatic disease)
- •Clinical indication to undergo palliative radiotherapy in the opinion of the treating physician
- •Able to undergo study procedures
- •More than 6 weeks post radiotherapy (at the time of the PET scan)
- •More than 6 weeks post chemotherapy or surgery (at the time of the PET scan), or 3 weeks is acceptable if disease has progressed on most recent chemotherapy.
- •Able to undergo study procedures
- •Lesion/s to be treated is/are radiologically measurable as per modified RECIST or RECIST
- •Baseline pain score on VAS greater than or equal to 4 AND/OR MED is greater or equal to 10mg/24 hours
Exclusion Criteria
- •Currently receiving chemotherapy or radiotherapy
- •Radiotherapy to same site
- •Intention to commence chemotherapy \< 6 weeks post radiotherapy
- •Pregnant or breastfeeding at the time of study enrolment
- •Unable to provide signed informed consent
- •Inadequate English language to complete study outcome measures
- •Medical contraindication to palliative radiotherapy
- •Geographically inaccessible for follow\-up
- •Less than 18 years of age
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prospective study of efficacy of palliative radiotherapy for advanced inoperable gastric cancer with active bleedinggastric cancerJPRN-UMIN000026362Asahi University31
Completed
Not Applicable
Investigation on radiotherapy treatment effect using perfusion and diffusion-weighted MR imagingtumorJPRN-UMIN000014439Kyoto Univerisity Hospital
Completed
Phase 2
Phase II study of palliative radiotherapy combined with Zoledronic Acid Hydrate for metastatic bone tumor from renal cell carcinomaRenal cancerJPRN-UMIN000007836Shizuoka Cancer Center Japanese Radiation Oncology Study Group30
Completed
Not Applicable
Quality of Life After Conformal Radiotherapy in Late Stage Oral Cavity Cancer:A Prospective clinical TrialCTRI/2018/03/012441Jawaharlal Institue of Postgraduate Medical Education and research25
Active, not recruiting
Phase 1
ABiochemically-relapsing prostate adenocarcinoma following radical prostatectomy.MedDRA version: 14.1 Level: LLT Classification code 10001186 Term: Adenocarcinoma of prostate System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004831-30-FRICANCER43